Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Overview of attention for article published in Cancer Discovery, April 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

So far, Altmetric has seen 94 X posts from 68 X users, with an upper bound of 607,038 followers.

RT @DrBetofMDPhD: Promising signals for #TIL in #NSCLC. Proud of you @AdamJSchoenfeld and colleagues!!

RT @OhioStateMedOnc: 📝New publication from Kai He & colleagues on Lifileucel, an Autologous #TIL Monotherapy, in Patients with Advanced #NS…

RT @ChristianRolfo: Very interesting study at ⁦@CD_AACR⁩ Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients w…

RT @ChristianRolfo: Very interesting study at ⁦@CD_AACR⁩ Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients w…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 90 additional X posts.